<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2020-02-05">2020 February 05</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">E</forename><surname>Young</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Noerenberg</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Mansouri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Ljungström</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Frick</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L-A</forename><surname>Sutton</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Blakemore</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Sciences</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Southampton</orgName>
								<address>
									<settlement>Southampton</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Galan-Sousa</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Plevova</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Central European Institute of Technology</orgName>
								<orgName type="institution" key="instit2">Masaryk University and University Hospital Brno</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Baliakas</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Rossi</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Translational Medicine</orgName>
								<orgName type="institution">Amedeo Avogadro University of Eastern Piedmont</orgName>
								<address>
									<settlement>Novara</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">Oncology Institute of Southern Switzerland and Institute of Oncology Research</orgName>
								<address>
									<settlement>Hematology, Bellinzona</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">R</forename><surname>Clifford</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Oxford National Institute for Health Research Biomedical Research Centre</orgName>
								<orgName type="institution" key="instit2">University of Oxford</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Roos- Weil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Navrkalova</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Central European Institute of Technology</orgName>
								<orgName type="institution" key="instit2">Masaryk University and University Hospital Brno</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">INSERM</orgName>
								<orgName type="institution" key="instit2">Institut Gustave Roussy</orgName>
								<address>
									<postCode>U1170</postCode>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Dörken</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><forename type="middle">E</forename><surname>Smedby</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Department of Medicine Solna</orgName>
								<orgName type="department" key="dep2">Clinical Epidemiology Unit</orgName>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">Karolinska Institutet, and Hematology Center</orgName>
								<orgName type="institution">Karolinska University Hospital</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Juliusson</surname></persName>
							<affiliation key="aff10">
								<orgName type="department" key="dep1">Department of Laboratory Medicine</orgName>
								<orgName type="department" key="dep2">Stem Cell Center</orgName>
								<orgName type="institution">Lund University</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">B</forename><surname>Giacopelli</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">The Ohio State University</orgName>
								<address>
									<settlement>Columbus</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Blachly</surname></persName>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">The Ohio State University</orgName>
								<address>
									<settlement>Columbus</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Belessi</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Hematology Department</orgName>
								<orgName type="institution">General Hospital of Nikea</orgName>
								<address>
									<settlement>Piraeus</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Panagiotidis</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">First Department of Propaedeutic Medicine</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">University of Athens</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">N</forename><surname>Chiorazzi</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution" key="instit1">Karches Center for Chronic Lymphocytic Leukemia Research</orgName>
								<orgName type="institution" key="instit2">The Feinstein Institute for Medical Research</orgName>
								<address>
									<settlement>Manhasset</settlement>
									<region>New York</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Davi</surname></persName>
							<affiliation key="aff15">
								<orgName type="laboratory">Laboratory of Hematology</orgName>
								<orgName type="institution" key="instit1">Universite Pierre et Marie Curie</orgName>
								<orgName type="institution" key="instit2">Hopital Pitie-Salpetriere</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Langerak</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">Department of Immunology</orgName>
								<orgName type="laboratory">Laboratory for Medical Immunology</orgName>
								<orgName type="institution" key="instit1">Erasmus MC</orgName>
								<orgName type="institution" key="instit2">University Medical Center</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Oscier</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Department of Molecular Pathology</orgName>
								<orgName type="institution">Royal Bournemouth Hospital</orgName>
								<address>
									<settlement>Bournemouth</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Schuh</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Oncology</orgName>
								<orgName type="institution" key="instit1">Oxford National Institute for Health Research Biomedical Research Centre</orgName>
								<orgName type="institution" key="instit2">University of Oxford</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Gaidano</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Translational Medicine</orgName>
								<orgName type="institution">Amedeo Avogadro University of Eastern Piedmont</orgName>
								<address>
									<settlement>Novara</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Ghia</surname></persName>
							<affiliation key="aff18">
								<orgName type="institution">Università Vita-Salute San Raffaele</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="department">Division of Experimental Oncology</orgName>
							</affiliation>
							<affiliation key="aff20">
								<orgName type="department">Department of Onco-Hematology</orgName>
								<orgName type="institution">Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute</orgName>
								<address>
									<settlement>Milan</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">W</forename><surname>Xu</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Collaborative Innovation Center For Cancer Personalized Medicine</orgName>
								<orgName type="institution" key="instit1">the First Affiliated Hospital of Nanjing Medical University</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Fan</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Collaborative Innovation Center For Cancer Personalized Medicine</orgName>
								<orgName type="institution" key="instit1">the First Affiliated Hospital of Nanjing Medical University</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Bernard</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution" key="instit1">INSERM</orgName>
								<orgName type="institution" key="instit2">Institut Gustave Roussy</orgName>
								<address>
									<postCode>U1170</postCode>
									<settlement>Villejuif</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Nguyen- Khac</surname></persName>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Rassenti</surname></persName>
							<affiliation key="aff15">
								<orgName type="laboratory">Laboratory of Hematology</orgName>
								<orgName type="institution" key="instit1">Universite Pierre et Marie Curie</orgName>
								<orgName type="institution" key="instit2">Hopital Pitie-Salpetriere</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Division of Hematology/Oncology</orgName>
								<orgName type="department" key="dep2">Department</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Li</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Collaborative Innovation Center For Cancer Personalized Medicine</orgName>
								<orgName type="institution" key="instit1">the First Affiliated Hospital of Nanjing Medical University</orgName>
								<orgName type="institution" key="instit2">Jiangsu Province Hospital</orgName>
								<address>
									<settlement>Nanjing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Kipps</surname></persName>
							<affiliation key="aff22">
								<orgName type="department" key="dep1">Division of Hematology/Oncology</orgName>
								<orgName type="department" key="dep2">Department</orgName>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">K</forename><surname>Stamatopoulos</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department" key="dep1">Institute of Applied Biosciences</orgName>
								<orgName type="department" key="dep2">Center for Research and Technology Hellas</orgName>
								<address>
									<settlement>Thessaloniki</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Pospisilova</surname></persName>
							<affiliation key="aff3">
								<orgName type="institution" key="instit1">Central European Institute of Technology</orgName>
								<orgName type="institution" key="instit2">Masaryk University and University Hospital Brno</orgName>
								<address>
									<settlement>Brno</settlement>
									<country key="CZ">Czech Republic</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Zenz</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department of Molecular Therapy in Haematology and Oncology (G250)</orgName>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Translational Oncology</orgName>
								<orgName type="department" key="dep2">National Center for Tumor Diseases (NCT)</orgName>
								<orgName type="department" key="dep3">German Cancer Research Center (DKFZ)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="department">Department of Medicine V</orgName>
								<orgName type="institution">University Hospital Heidelberg</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="institution">German Consortium for Translational Cancer Research (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Strefford</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Cancer Sciences</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Southampton</orgName>
								<address>
									<settlement>Southampton</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="department" key="dep1">Division of Hematology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">The Ohio State University</orgName>
								<address>
									<settlement>Columbus</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><roleName>Professor</roleName><forename type="first">R</forename><surname>Rosenquist</surname></persName>
							<email>richard.rosenquist@igp.uu.se.</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">F</forename><surname>Damm</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Department of Hematology, Oncology, and Tumor Immunology</orgName>
								<orgName type="institution">University Medical Center</orgName>
								<address>
									<settlement>Charité, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="institution">German Consortium for Translational Cancer Research (DKTK)</orgName>
								<address>
									<settlement>Heidelberg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="institution">Berlin Institute of Health (BIH)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff23">
								<orgName type="department">Department of Immunology, Genetics, and Pathology</orgName>
								<orgName type="laboratory">Science for Life Laboratory</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<postCode>SE-75185</postCode>
									<settlement>Uppsala</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff24">
								<orgName type="department">of Medicine</orgName>
								<orgName type="institution">University of California at San Diego/Moores Cancer Center</orgName>
								<address>
									<settlement>La Jolla</settlement>
									<region>CA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2020-02-05">2020 February 05</date>
						</imprint>
					</monogr>
					<idno type="MD5">C17C1FE94B9EBD9C7CC6EBBBB19B687D</idno>
					<idno type="DOI">10.1038/leu.2016.359</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:28+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome.</s><s>To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n = 1283) and two validation cohorts (UK CLL4 trial patients, n = 366; CLL Research Consortium (CRC) patients, n = 490).</s><s>Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations.</s><s>EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes.</s><s>EGR2-mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%).</s><s>EGR2 mutations independently predicted shorter time-tofirst-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort.</s><s>A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations.</s><s>In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>INTRODUCTION</head><p><s>Chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, <ref type="bibr" target="#b0">1</ref> is a malignancy of mature B lymphocytes that accumulate in the blood, bone marrow and other lymphoid tissues. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref></s><s>Although treatment has undergone profound improvements in recent years, <ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> CLL shows a remarkable clinical variability, which is likely to be reflective of a large biological heterogeneity. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref></s><s><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref> More recently, whole-genome sequencing and whole-exome sequencing studies have begun to unravel the molecular landscape of CLL, revealing a limited number of frequently mutated genes (for example, ATM, NOTCH1, SF3B1, TP53) <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> with a long tail of genes altered in &lt; 5% of cases (for example, CHD2, <ref type="bibr" target="#b14">15</ref> MED12, <ref type="bibr" target="#b15">16</ref> NFKBIE, <ref type="bibr" target="#b16">17</ref> POT1, <ref type="bibr" target="#b17">18</ref> RPS15, <ref type="bibr" target="#b18">19</ref> SETD2, 20 XPO1 <ref type="bibr" target="#b20">21</ref> ).</s><s>Though integration of molecular information has been proposed to improve classical risk stratification models, <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> a substantial proportion of patients with a dismal clinical course will not be captured by these algorithms, hence indicating a need to identify additional molecular markers of disease aggressiveness.</s></p><p><s>Recurrent missense mutations within the EGR2 (early growth response 2) gene, a versatile transcription factor involved in differentiation of hematopoietic cells, <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref> were recently reported in ~8% of advanced-stage CLL patients and appeared to be associated with a worse outcome.</s><s>29 Notably, EGR2 mutations were predominantly observed within the three zincfinger domains located in exon 2. EGR2 is activated through ERK phosphorylation upon Bcell receptor (BcR) stimulation, <ref type="bibr" target="#b25">26</ref> and we have previously shown that EGR2-mutated CLL patients display altered expression of EGR2 down-stream target genes compared with patients wild-type for EGR2, thus pointing to a pathogenic role for EGR2 mutations through dysregulated BcR signalling. <ref type="bibr" target="#b28">29</ref></s><s>In addition, global DNA methylation investigations linked abnormal EGR2 activity with aberrant hypomethylation of transcription factor binding sites in CLL. <ref type="bibr" target="#b29">30</ref> In this study, we investigated the frequency, clinical and biological associations, and prognostic impact of EGR2 mutations in a large well-characterized screening cohort (n = 1283), two validation cohorts comprising untreated patients from the LRF UK CLL4 trial (n = 366) and patient samples from the CLL Research Consortium (CRC, n = 490), a Chinese CLL cohort (n = 233) and Richter's syndrome patients (n = 31).</s><s>EGR2 mutations were associated with younger age, more advanced disease and other molecular high-risk markers, and remained as an independent factor predicting poor outcome both in the screening and validation cohort.</s><s>These findings suggest that EGR2 mutations define a new, poorprognostic subgroup of the disease.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Peripheral blood samples from 1283 CLL patients with tumor content ⩾ 60% (median 94%) were collected from collaborating institutions in the Czech Republic, France, Germany, Greece, Italy, the Netherlands, Sweden, and the United States and comprized the screening cohort.</s><s>All CLL cases were diagnosed according to the iwCLL guidelines and displayed a typical CLL phenotype. <ref type="bibr" target="#b30">31</ref></s><s>Over 76% of samples were collected before treatment and within a median of 7 months from time of diagnosis (EGR2-mutated cases, median 2 months).</s><s>Clinical and biological characteristics of the screening cohort are summarized in Table <ref type="table" target="#tab_0">1</ref>; this cohort had a lower median age at diagnosis and a higher proportion of IGHV-unmutated cases compared with 'general' CLL cohorts, likely reflecting that several of the participating institutions are referral centers.</s><s>In addition, 366 CLL patients, entered into the multicenter trial UK LRF CLL4 (a randomized first-line comparison of chlorambucil, fludarabine and fludarabine plus cyclophosphamide) served as the first validation cohort (Supplementary Table <ref type="table" target="#tab_0">S1</ref>).</s><s>Details of the CLL4 treatment protocol have been previously reported. <ref type="bibr" target="#b31">32</ref></s><s>Four hundred and ninety patients collected within the CRC served as the second validation cohort (Supplementary Table <ref type="table" target="#tab_1">S2</ref>) with 81% samples obtained before treatment start.</s><s>Finally, 233 cases from a Chinese CLL patient cohort (Supplementary Table <ref type="table" target="#tab_3">S3</ref>), as well as 31 patients with Richter's syndrome were also screened for EGR2 mutations.</s><s>Written consent was obtained in accordance with the Declaration of Helsinki and with ethical approval obtained from the local ethics committees.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of EGR2 mutations</head><p><s>The EGR2 mutational hotspot region, covering the three zinc-finger domains located in exon 2, was screened as follows: Sanger sequencing was performed to analyze 1048 CLL and 31 Richter's syndrome patients; 622 cases were investigated using targeted next-generation sequencing (NGS), 171 patients were assessed by both techniques, and in 490 patients MassARRAY iPLEX assay was applied.</s><s>In addition, for 41 patients in the screening cohort EGR2 mutation status was derived from whole-exome sequencing data. <ref type="bibr" target="#b18">19</ref></s><s>Bidirectional Sanger sequencing was performed according to standard protocols (primers available on request). <ref type="bibr" target="#b32">33</ref></s><s>For targeted NGS, a 500 bp amplicon was bead-purified and library preparation was performed using the Nextera XT (Illumina, CA, USA) kit.</s><s>Libraries were sequenced on the MiSeq instrument using v2 sequencing chemistry (Illumina).</s><s>Applying standard settings, sequences were mapped using the alignment tool BWA (v.0.7.12). <ref type="bibr" target="#b33">34</ref></s><s>Variant calling was carried out using VarScan 2 (v.2.3.7) <ref type="bibr" target="#b34">35</ref></s><s>with a minimum variant allele frequency (VAF) of 0.5% and variants were annotated using Annovar. <ref type="bibr" target="#b35">36</ref></s><s>Samples from 366 patients enrolled in the UK LRF CLL4 trial were investigated by targeted NGS using a custom design TruSeq gene panel (Illumina) that included the entire coding region of EGR2. <ref type="bibr" target="#b19">20</ref></s><s>Approximately 490 CRC samples were analyzed using the MassARRAY iPLEX assay (Agena, CA, USA) for recurrent mutations at EGR2 amino acid positions 356, 384 and 411/12; all mutated samples were validated by targeted NGS of a 210 bp amplicon using MiSeq (Illumina).</s><s>Samples with &gt;5% VAF were considered mutated.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of concurrent mutations by targeted deep-sequencing</head><p><s>Thirty-eight EGR2-mutated patients (including 5 patients with VAF &lt;5%) were analyzed using Haloplex technology (Agilent Technologies, CA, USA) according to the manufacturer's protocol.</s><s>Probes targeting all coding exons or hotspot regions of 27 known CLL driver genes and/or genes previously reported in EGR2-mutated CLL <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref> were designed using Agilent's SureDesign service (https://earray.chem.agilent.com/suredesign/</s><s>home.htm;</s><s>Supplementary Table <ref type="table">S4</ref>).</s><s>Cluster generation and 125 cycle paired-end sequencing of the pooled library over one lane of the HiSeq 2500 instrument using v4 sequencing chemistry was performed (Illumina).</s><s>Illumina sequencing adapters were removed using TrimGalore (v.0.3.7) and trimmed reads were aligned to the hg19 human reference genome (February 2009 assembly) using BWA (v.0.7.12).</s><s>Variants were detected using VarScan2 with a VAF cutoff of 5% and a minimum 30 reads covering the variant was required.</s><s>Non-synonymous single nucleotide variants and insertions/deletions (indels) that were not present in the 1000 genomes database were included for downstream analyses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Mutational frequencies were assessed using two-sided, descriptive statistics.</s><s>Overall survival (OS) was calculated from date of diagnosis or time from randomization (UK LRF CLL4) until last follow-up or death, while time-to-first-treatment (TTFT) was calculated from date of diagnosis until initial treatment.</s><s>Kaplan-Meier analysis was performed to construct survival curves and the Cox-Mantel log rank test was used to determine differences between groups.</s><s>Cox regression analysis was applied to compare the prognostic significance of EGR2 mutations in relation to other prognostic markers.</s><s>A significance level of p &lt; 0.05 was applied and all statistical analyses were performed using Statistica Software 13.0 (Dell Inc., OK, USA).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p><s>EGR2 mutations and their association with patient characteristics The overall prevalence of EGR2 mutations in this study was 3.8% (91/2403 patients).</s><s>In detail, EGR2 mutations were detected in 50/1283 CLL patients (3.9%) of the screening cohort, in 12/366 patients (3.3%) of the UK CLL4 trial cohort, and in 18/490 of the CRC cohort (3.7%; Figure <ref type="figure" target="#fig_0">1a</ref>; Supplementary Table <ref type="table">S5</ref>).</s><s>Further screening revealed that 9/233 (3.9%) patients in the Chinese cohort, and 2/31 (6.5%) Richter's syndrome patients carried an EGR2 mutation (Figure <ref type="figure" target="#fig_0">1a</ref>;Supplementary Table <ref type="table">S5</ref>).</s></p><p><s>All mutations represented heterozygous missense mutations except for a recurrent in-frame 3-bp insertion identified in 3 cases.</s><s>The majority of EGR2 mutations (85/91, 93%) were localized to the DNA-binding sites of the 3 zinc-finger domains, and predominantly affected codons E356, H384 and D411 (Figure <ref type="figure" target="#fig_0">1b</ref>).</s><s>These domains are highly conserved between orthologues in different species (Supplementary Figure <ref type="figure" target="#fig_0">S1</ref>).</s><s>The somatic nature of EGR2 mutations affecting codons E356, H384, D411, and E412 has been previously confirmed. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b28">29</ref></s><s>With the exception of R318Q, all identified amino acid substitutions were predicted damaging with a SIFT score &lt;0.05. <ref type="bibr" target="#b44">45</ref></s><s>r 49 EGR2-mutated samples from the screening cohort and all patients from the two validation cohorts, information on allelic frequency was available from deep-sequencing and the median VAFs were 38.9%, 36.3% (UK CLL4 trial) and 39% (CRC cohort), respectively (range, 5.6-62%).</s><s>In addition, 33 patients were found to exhibit low-frequency EGR2 variants at the aforementioned hotspot codons with a VAF ranging from 0.5 to 5%.</s><s>However, only 14/33 (42%) of these variants could be verified in an independent experiment (Supplementary Table <ref type="table">S6</ref>).</s><s>These low-frequency EGR2 mutations were excluded from subsequent survival analyses.</s></p><p><s>We next evaluated the correlation between clinico-biological characteristics and EGR2 mutation status in all 1283 patients included in the screening cohort (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Compared with wild-type cases, EGR2-mutated patients were significantly younger (57 vs 62 years; P = 0.0042), more often presented with an advanced Binet stage at diagnosis (Binet B/C 56 vs 30%; P = 0.0005), carried unmutated IGHV genes (81 vs 61%; P = 0.0041) and del(11)(q22) (33 vs 18%; P = 0.0161), as well as expressed high levels of CD38 (67 vs 27%; P &lt; 0.0001).</s></p><p><s>Co-existing mutations and clonal dynamics of EGR2-mutated CLL Through targeted enrichment, we investigated 27 known CLL driver genes and/or genes previously reported in EGR2-mutated patients <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref><ref type="bibr" target="#b39">[40]</ref><ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref> in 38 EGR2-mutated CLL patients (including 5 cases with VAF &lt; 5%).</s><s>Overall, a mean coverage of 4100 reads per targeted region was achieved with at least 500 reads in 95% and 1000 reads in 90% per nucleotide base of the targeted regions (Supplementary Table <ref type="table">S7</ref>), hence allowing reliable detection of co-existing mutations.</s><s>A total of 92 nonsynonymous alterations were detected (Supplementary Table <ref type="table">S8</ref>); 15 cases harbored one, 8 showed two, 5 patients had three and a single patient presented with four additional gene mutations (Figure <ref type="figure" target="#fig_0">1c</ref>), while no additional mutations were detected in the remaining 9 EGR2-mutated cases.</s><s>Mutations occurred most frequently in ATM (12/38, 31.6%),</s><s>TP53 (7/38, 18.4%) and SF3B1 (4/38, 10.5%).</s><s>Of note, 4/12 ATM-mutated cases had two ATM mutations and another 5 cases showed del(11q), resulting in a high frequency of multiple ATM aberrations in EGR2-mutated CLL (9/12, 75%).</s><s>Alterations affecting the NOTCH signalling pathway were found in 7 patients (18.4%;</s><s>NOTCH1 (n = 3), FBXW7 (n = 3) and SPEN (n = 1); Figure <ref type="figure" target="#fig_0">1c</ref>).</s><s>Similar findings were observed when comparing identified mutation frequencies with published whole-exome sequencing data from 964 EGR2-wildtype patients, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref> showing a significant enrichment of ATM (31.6 vs 10.9%, P &lt; 0.001, two-sided Fisher's exact), TP53 (18.4 vs 5.4%, P = 0.005, two-sided Fisher's exact) and FBXW7 (7.9 vs 1.8%, P = 0.036, two-sided Fisher's exact) mutations.</s></p><p><s>To gain insights into the clonal dynamics of EGR2-mutated CLL patients, we studied the VAF derived from whole-exome sequencing data before fludarabine, cyclophosphamide, and rituximab treatment and at relapse in five patients with available samples from both time points.</s><s>A sixth patient was sampled one year after diagnosis and again 7 years later; however remaining untreated at both time points.</s><s>All samples at both times had been negatively selected for CD5 + /CD19 + cells to ensure a high tumor content (&gt;95%).</s><s>In all six patients, the clone harboring an EGR2 mutation expanded during the clinical course and became the dominant clone at relapse or at follow-up (Figure <ref type="figure" target="#fig_0">1d</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical impact of EGR2 mutations</head><p><s>In the screening cohort (1178 cases with available clinical data), the median follow-up time for patients who remained alive was 87.5 months (interquartile range, 49.1 to 138.3 months).</s><s>Patients with mutated EGR2 (VAF &gt;5%) had a significantly worse TTFT (median, 7.8 vs 38.5 months; HR 1.86, 95% CI 1.35-2.57,</s><s>P &lt; 0.001; Figure <ref type="figure" target="#fig_2">2a</ref>) and OS as compared with EGR2-wild-type patients (median, 74.7 vs 127.2 months; HR 2.03, 95% Ci 1.41-2.92,</s><s>P&lt;0.001; Figure <ref type="figure" target="#fig_2">2b</ref>).</s><s>No survival difference was observed neither between patients with TP53abn and EGR2 mutations (P = 0.900; Figures <ref type="figure" target="#fig_2">2c and d</ref>), nor between EGR2-mutated patients with or without concomitant ATM lesions (P=0.665;</s><s>Supplementary Figure <ref type="figure" target="#fig_2">S2</ref>).</s><s>Notably, within the subgroup of 691 U-CLL patients, EGR2-mutated cases (n = 39) showed a significantly inferior OS than wild-type cases (P = 0.009;Supplementary Figure <ref type="figure" target="#fig_3">S3</ref>).</s><s>Similarly, among the 164 patients with TP53abn, a high-risk group defined by a concomitant EGR2 mutation with a shorter OS was identified (P = 0.023; Supplementary Figure <ref type="figure">S4</ref>).</s></p><p><s>In multivariate analysis, EGR2 mutations remained an independent negative prognostic marker both for TTFT (HR 1.44, 95% CI 1.01-2.06;P</s><s>= 0.047) and OS (HR 1.72, 95% CI 1.12-2.65,</s><s>P = 0.014; Table <ref type="table" target="#tab_1">2</ref>), when including EGR2 mutation status, age, gender, Binet stage, IGHV mutational status, del(11q) and TP53abn in the model.</s><s>This independent effect on shorter TTFT and OS remained significant also when including additional molecular markers to the model such as NOTCH1 and SF3B1 mutations (Supplementary Table <ref type="table">S9</ref>).</s></p><p><s>In the UK CLL4 trial cohort (n = 366), the median follow-up time for patients who remained alive was 145 months (interquartile range, 127.7-157 months).</s><s>Among the 12 EGR2mutated cases treated within the CLL4 trial, 7 patients were randomly assigned to the fludarabine plus cyclophosphamide arm, 5 patients received chlorambucil and none fludarabine treatment.</s><s>In univariate analysis, EGR2 mutations were significantly associated with a reduced median OS from time of randomization of 24.6 versus 75.7 months for mutated vs. wild-type patients, respectively (HR 1.71, 95% CI 1.30-2.25,</s><s>P = 0.004; Figures <ref type="figure" target="#fig_3">3a and b</ref>).</s><s>Multivariate analysis confirmed EGR2 mutation status as an independent risk factor for OS (HR 1.95, 95% CI 1.02-3.73,</s><s>P = 0.043;Table <ref type="table" target="#tab_3">3</ref>).</s></p><p><s>In the CRC cohort (486 cases with available clinical data), the median follow-up time for patients who remained alive was 64.9 months (interquartile range, 35.6-103.7 months).</s><s>In univariate analysis, EGR2 mutations were significantly associated with a shorter TTFT (median, 35.8 vs 55.7 months;HR 2.08, 95% CI 1.21-3.57,</s><s>P = 0.007;Figure <ref type="figure" target="#fig_3">3c</ref>) and reduced median OS of 98.3 versus 152.9 months for mutated vs wild-type patients, respectively (HR: 2.22, 95% CI 1.03-4.77,</s><s>P = 0.036; Figure <ref type="figure" target="#fig_3">3d</ref>).</s><s>Lack of cytogenetic/ molecular data in a substantial proportion of CRC patients precluded testing of the above multivariate model.</s><s>Nevertheless, multivariate analysis including age, gender, IGHV and EGR2 mutation status, confirmed EGR2 as an independent risk factor for TTFT (HR 1.92, 95% CI 1.11-3.32,</s><s>P = 0.020), while only a borderline significance was seen for OS (HR 1.90, 95% CI 0.88-4.12,</s><s>P = 0.10; Supplementary Table <ref type="table" target="#tab_0">S10</ref>), probably because of relatively few events and shorter median follow-up time in this cohort.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p><s>Missense mutations within the EGR2 gene were recently reported in progressive and/or relapsing CLL patients and hence indicated to be associated with a worse clinical outcome. <ref type="bibr" target="#b28">29</ref></s><s>Here, by investigating large well-characterized cohorts, we not only confirm and significantly extend this observation, but also reveal that EGR2-mutated CLL patients display distinctive clinicobiological features and a rapidly progressive disease course.</s><s>Indeed, survival analysis in our screening cohort demonstrated a significant, negative prognostic impact of EGR2 mutations with markedly short TTFT and OS, similar to patients with TP53abn, that remained as an independent negative factor in multivariate analysis.</s><s>While EGR2 mutations were confirmed as a high-risk marker of short TTFT and OS in the CRC cohort, they were also shown to independently predict short OS from time of randomization in the UK CLL4 trial cohort.</s><s>Importantly, the negative prognostic impact of EGR2 mutations was also evident in aggressive subgroups, such as U-CLL and patients with TP53 aberrations, which displayed a particularly short OS.</s><s>Taken together, our data support that EGR2 mutations define a new subgroup of patients with a particularly dismal outcome.</s><s>This comprehensive analysis identified EGR2 mutations in 3.8% of 2403 investigated patients with similar mutation frequencies in the different cohorts analyzed (range, 3.3-3.9%),</s><s>although different techniques for mutation screening were used.</s><s>This relatively low mutation rate reflects the known genetic heterogeneity in CLL, with only a handful of genes mutated in 10-20% of cases, but with a long list of gene mutations occurring in less than 5% of CLL cases. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b13">14</ref></s><s>Notably, no difference was observed between European/American and Chinese CLL patients with respect to their EGR2 mutation frequencies as suggested for other known CLL drivers such as SF3B1. <ref type="bibr" target="#b45">46</ref></s><s><ref type="bibr" target="#b48">[49]</ref> EGR2 mutations were often detected with a high mutant allele burden (median VAF 38.9%; Supplementary Table <ref type="table" target="#tab_0">S11</ref>), indicating that these aberrations occur early in CLL development.</s><s>29 From our targeted NGS panel, we noted that patients with EGR2 mutations frequently displayed concurrent mutations in DNA damage response, including, ATM and TP53 and in NOTCH signalling pathway, that is, NOTCH1 and FBXW7, indicating that aberrations within these pathways are important contributors to the evolution of the aggressive phenotype in EGR2-mutated patients.</s><s>1]<ref type="bibr" target="#b51">[52]</ref> Bi-allelic ATM inactivation is known to be associated with a shorter TTFT and OS. <ref type="bibr" target="#b49">50</ref></s><s>Collectively, our data indicate an accumulation of several distinct poor-prognostic markers in EGR2-mutated CLL.</s></p><p><s>Although most EGR2 mutations were deemed to be clonal, we observed a minor proportion of patients (n = 14) with a low EGR2 mutation burden (&lt;5% VAF, confirmed by independent experiments).</s><s>Survival analysis revealed a trend for shorter OS in these low-burden cases compared with wild-type patients (P = 0.11; Supplementary Figure <ref type="figure">S5</ref>).</s><s>Furthermore, serial sampling in five treated CLL cases revealed an expansion of the EGR2-mutated subclone over the clinical course and at relapse (Figure <ref type="figure" target="#fig_0">1d</ref>; Supplementary Figure <ref type="figure">S6</ref>).</s><s>Interestingly, one additional case that remained untreated also showed an expansion of the EGR2-mutated clone.</s><s>This preferential selection of molecularly defined subclones under pressure of chemotherapy is similar to other poor-prognostic markers such as TP53 in CLL <ref type="bibr" target="#b52">53</ref> and BCOR in myelodysplastic syndromes. <ref type="bibr" target="#b53">54</ref></s><s>Larger studies are now warranted to further analyze the potential clinical impact of low-frequency EGR2 mutations as was recently shown for TP53 and NOTCH1. <ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b54">55</ref></s><s>milar to the pivotal studies, <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30</ref> EGR2 mutations were clustered in DNA binding domains pointing to a pathogenic role for the hotspots in codons E356, H384 and D411.</s><s>The functional role of mutated EGR2 in leukemogenesis is however still poorly understood.</s><s>We recently showed that mutations in the EGR2 DNA binding domain affect cell cycle behavior and lead to altered transcriptional activity and dysregulated BcR signalling. <ref type="bibr" target="#b28">29</ref></s><s>Oakes et al. also identified altered EGR2 activity as a mediator for hypomethylation of distinct transcription factor binding sites. <ref type="bibr" target="#b29">30</ref></s><s>Whether these effects are restricted to mutations localized in the three sites within the EGR2 DNA binding domain remains to be addressed.</s><s>Nevertheless, considering the potential role of mutated EGR2 in altering BcR signalling, it will be particularly relevant to study the efficacy of BcR inhibitors in this patient subgroup.</s></p><p><s>In summary, our novel data highlight EGR2 mutations as an adverse prognostic biomarker for CLL.</s><s>EGR2 appears to identify a subgroup of CLL patients with a particularly dismal outcome similar to patients with TP53abn.</s><s>On confirmation of our current data in other cohorts, in particular in patients treated with novel agents (for example, ibrutinib and</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc><div><p><s>Figure 1.</s></p></div></figDesc><graphic coords="13,147.72,62.00,376.56,460.80" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Frequency, localization and</head><label></label><figDesc><div><p><s>dynamics of EGR2 mutations.</s><s>(a) Frequency of EGR2 mutations in investigated cohorts.</s><s>(b) Localization of mutations identified in EGR2.</s><s>(c) Coexisting mutations in 38 EGR2-mutated CLL patients.</s><s>(d) Clonal dynamics of six EGR2mutated CLL patients.</s><s>The first 5 patients received FCR therapy between the first (blue bars) and second (green bars) time point sample, while the last patient remained untreated at the second time point (7 years between the samples).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc><div><p><s>Figure 2. Clinical impact of EGR2 mutations in 1178 CLL patients from the screening cohort.</s><s>(a) Time-to-first-treatment and (b) overall survival in the screening cohort according to EGR2 mutation status.</s><s>(c) Time-to-first-treatment and (d) overall survival in the screening cohort according to the established hierarchy for genomic aberrations 9 and EGR2 mutation status.</s><s>Patients with TP53abn and concomitant EGR2 mutation are grouped into the TP53abn group (TTFT, n = 7; OS, n = 8).</s></p></div></figDesc><graphic coords="14,104.16,62.00,463.68,355.44" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc><div><p><s>Figure 3. Clinical impact of EGR2 mutations in 366 patients from the UK LRF CLL4 trial and 486 patients from the CRC cohort.</s><s>(a) Overall survival in the UK CLL4 validation cohort according to EGR2 mutation status.</s><s>(b) Overall survival in the UK CLL4 validation cohort according to the established hierarchy for genomic aberrations 9 and EGR2 mutation status.</s><s>Patients with TP53abn and concomitant EGR2 mutation are grouped into the TP53abn group (n = 1).</s><s>(c) Time-to-first-treatment and (d) overall survival in the CRC validation cohort according to EGR2 mutation status.</s></p></div></figDesc><graphic coords="15,102.72,62.00,466.56,355.26" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Comparison of clinical and biological characteristics between EGR2 mutated and wild-type CLL patients within the screening cohort (n = 1283)</s></p></div></figDesc><table><row><cell></cell><cell cols="2">EGR2 wild-type n = 1233 EGR2 mutated n=50</cell><cell>P-value</cell></row><row><cell>Age</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Median (years)</cell><cell>62.1</cell><cell>57.4</cell><cell>0.0042</cell></row><row><cell>&lt;55 years-no. (%)</cell><cell>278 (25%)</cell><cell>17 (35%)</cell><cell></cell></row><row><cell>&gt;71 years-no. (%)</cell><cell>194 (17%)</cell><cell>5 (10%)</cell><cell></cell></row><row><cell>No information</cell><cell>105</cell><cell>1</cell><cell></cell></row><row><cell>Sex</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Female-no. (%)</cell><cell>393 (34%)</cell><cell>19 (40%)</cell><cell>0.3490</cell></row><row><cell>Male-no. (%)</cell><cell>769 (66%)</cell><cell>28 (60%)</cell><cell></cell></row><row><cell>No information</cell><cell>71</cell><cell>3</cell><cell></cell></row><row><cell>Binet stage</cell><cell></cell><cell></cell><cell></cell></row><row><cell>A-no. (%)</cell><cell>674 (70%)</cell><cell>17 (44%)</cell><cell>0.0005</cell></row><row><cell>B/C-no. (%)</cell><cell>290 (30%)</cell><cell>22 (56%)</cell><cell></cell></row><row><cell>No information</cell><cell>269</cell><cell>11</cell><cell></cell></row><row><cell>Need of treatment</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes-no. (%)</cell><cell>726 (68%)</cell><cell>42 (91%)</cell><cell>0.0010</cell></row><row><cell>No-no. (%)</cell><cell>334 (32%)</cell><cell>4 (9%)</cell><cell></cell></row><row><cell>No information</cell><cell>173</cell><cell>4</cell><cell></cell></row><row><cell>CD38 +</cell><cell></cell><cell></cell><cell></cell></row><row><cell>High (&gt;30%)-no. (%)</cell><cell>161 (27%)</cell><cell>20 (67%)</cell><cell>&lt; 0.0001</cell></row><row><cell>Low (≤30%)-no. (%)</cell><cell>438 (73%)</cell><cell>10 (33%)</cell><cell></cell></row><row><cell>No information</cell><cell>634</cell><cell>20</cell><cell></cell></row><row><cell>IGHV</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Mutated-(&lt;98% identity)-no. (%)</cell><cell>460 (39%)</cell><cell>9 (19%)</cell><cell>0.0041</cell></row><row><cell>Unmutated (≥98% identity)-no. (%)</cell><cell>710 (61%)</cell><cell>39 (81%)</cell><cell></cell></row><row><cell>No information</cell><cell>63</cell><cell>2</cell><cell></cell></row><row><cell>del(13)(q14)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent-no. (%)</cell><cell>665 (64%)</cell><cell>35 (81%)</cell><cell>0.0194</cell></row><row><cell>Present-no. (%)</cell><cell>374 (36%)</cell><cell>8 (19%)</cell><cell></cell></row><row><cell>No information</cell><cell>194</cell><cell>7</cell><cell></cell></row><row><cell>del(11)(q22)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent-no. (%)</cell><cell>852 (82%)</cell><cell>29 (67%)</cell><cell>0.0161</cell></row><row><cell>Present-no. (%)</cell><cell>187 (18%)</cell><cell>14 (33%)</cell><cell></cell></row><row><cell>No information</cell><cell>194</cell><cell>7</cell><cell></cell></row><row><cell>+ 12</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Absent-no. (%)</cell><cell>927 (89%)</cell><cell>36 (84%)</cell><cell>0.2587</cell></row><row><cell>Present-no. (%)</cell><cell>112 (11%)</cell><cell>7 (16%)</cell><cell></cell></row><row><cell>No information</cell><cell>194</cell><cell>7</cell><cell></cell></row><row><cell>TP53abn</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Multivariate Cox proportional hazard analysis of time-to-first-treatment (TTFT, cases,</s></p></div></figDesc><table><row><cell>n = 863;</cell></row><row><cell>n = 624) and overall survival (OS, cases,</cell></row><row><cell>n = 898; events,</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Variable TTFT OS Hazard ratio 95% Confidence interval P-value Hazard ratio 95% Confidence interval P-value</head><label></label><figDesc></figDesc><table><row><cell>0.014</cell><cell>&lt;0.001</cell><cell>0.016</cell><cell>&lt;0.001</cell><cell>&lt;0.001</cell><cell>0.190</cell><cell>&lt;0.001</cell><cell></cell></row><row><cell>1.12-2.65</cell><cell>1.78-2.72</cell><cell>1.05-1.65</cell><cell>1.82-2.81</cell><cell>2.54-4.25</cell><cell>0.64-1.09</cell><cell>1.26-2.18</cell><cell></cell></row><row><cell>EGR2 mutation status 1.44 1.01-2.06 0.047 1.72</cell><cell>Age 1.04 0.89-1.22 0.611 2.20</cell><cell>Gender 1.11 0.94-1.31 0.230 1.32</cell><cell>Binet stage NA NA NA 2.26</cell><cell>IGHV mutation status 4.18 3.41-5.12 &lt;0.001 3.28</cell><cell>del(11q)(q22) 1.05 0.87-1.27 0.620 0.84</cell><cell>TP53abn 1.31 1.06-1.62 0.013 1.66</cell><cell>Abbreviations: NA, not applicable; TP53abn, TP53 aberrations (that is, mutations and or deletions).</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Multivariate Cox proportional hazard analysis of overall survival in the UK LRF CLL4 patients (cases, n = 297; events, n = 231) TP53 aberrations (that is, mutations and/or deletions).</s></p></div></figDesc><table><row><cell>Variable</cell><cell cols="3">Hazard ratio 95% Confidence interval P-value</cell></row><row><cell>EGR2 mutation status</cell><cell>1.95</cell><cell>1.02-3.73</cell><cell>0.043</cell></row><row><cell>Age</cell><cell>1.72</cell><cell>1.32-2.24</cell><cell>&lt;0.001</cell></row><row><cell>Gender</cell><cell>1.44</cell><cell>1.04-1.99</cell><cell>0.029</cell></row><row><cell>Binet stage</cell><cell>1.21</cell><cell>0.86-1.71</cell><cell>0.271</cell></row><row><cell>IGHV mutation status</cell><cell>2.22</cell><cell>1.64-2.99</cell><cell>&lt;0.001</cell></row><row><cell>del(11q)(q22)</cell><cell>1.46</cell><cell>1.07-1.99</cell><cell>0.018</cell></row><row><cell>TP53abn</cell><cell>4.85</cell><cell>2.90-8.11</cell><cell>&lt;0.001</cell></row><row><cell>Abbreviation: TP53abn,</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Leukemia. Author manuscript; available in PMC 2020 February 05.</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p><s>This study was supported by grants #2015_A09 from the Else-Kröner-Fresenius-Stiftung, #DA1787/1-1 from the Deutsche Forschungsgemeinschaft, the Lady Tata Memorial Trust (all F.D.), the Swedish Cancer Society, the Swedish Research Council, Uppsala University, Uppsala University Hospital, the Lion's Cancer Research Foundation, Uppsala, Marcus Borgström's Foundation, Uppsala, and Selander's Foundation, Uppsala, the research grants MSMT CR CEITEC2020 (LQ1601), and AZV MZCR <ref type="bibr" target="#b14">15</ref></s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Refer to Web version on PubMed Central for supplementary material.</s><s>Abbreviation: TP53abn, TP53 aberrations (that is, mutations and/or deletions).</s><s>Recurrent genomic aberrations were classified according to the Döhner classification.</s><s>9 A two-sided student's t-test was used to assess differences in age at diagnosis, while a Chi-square test was applied to evaluate all other variables in EGR2 wild-type versus mutated cases.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Manuscript</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<monogr>
		<title level="m" type="main">SEER stat fact sheets: chronic lymphocytic leukemia</title>
		<author>
			<persName><surname>Institute</surname></persName>
		</author>
		<author>
			<persName><surname>Nc</surname></persName>
		</author>
		<ptr target="http://seer.cancer.gov/statfacts/html/clyl.html" />
		<imprint>
			<date type="published" when="2013-05">May 2013</date>
			<biblScope unit="page">15</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The molecular pathogenesis of chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dalla-Favera</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="145" to="162" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26911189</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">From pathogenesis to treatment of chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Zenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mertens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kuppers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="37" to="50" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 19956173</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Byrd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Barrientos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Reddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">371</biblScope>
			<biblScope unit="page" from="213" to="223" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24881631</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Idelalisib and rituximab in relapsed chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Furman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Sharman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hillmen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="997" to="1007" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24450857</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Davids</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Kahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Puvvada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Gerecitano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">374</biblScope>
			<biblScope unit="page" from="311" to="322" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26639348</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rosenquist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Cancer Biol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="22" to="35" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25963298</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Damm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nguyen-Khac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fontenay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Bernard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2027" to="2031" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22484420</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Genomic aberrations and survival in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leupolt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Krober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bullinger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="page" from="1910" to="1916" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>PubMed: 11136261</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Damle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wasil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ghiotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Valetto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Allen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1840" to="1847" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10477712</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hamblin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gardiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Oscier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">K</forename><surname>Stevenson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1848" to="1854" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note>PubMed: 10477713</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rosenquist</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="7" to="16" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25552678</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Noncoding recurrent mutations in chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Puente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Valdes-Mas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gutierrez-Abril</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Martin-Subero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">526</biblScope>
			<biblScope unit="page" from="519" to="524" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26200345</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Mutations driving CLL and their evolution in progression and relapse</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Landau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Tausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">N</forename><surname>Taylor-Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bahlo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">526</biblScope>
			<biblScope unit="page" from="525" to="530" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26466571</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bretones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Quesada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Arango</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="195" to="202" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 26031915</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kampjarvi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Jarvinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Heikkinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ruppert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Senter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Hoag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="1884" to="1888" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25595892</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Mansouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ljungstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bondza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Arngarden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhoi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">212</biblScope>
			<biblScope unit="page" from="833" to="843" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25987724</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ramsay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Quesada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Foronda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Conde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Martinez-Trillos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="526" to="530" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23502782</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations</title>
		<author>
			<persName><forename type="first">V</forename><surname>Ljungstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cortese</forename><forename type="middle">D</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pandzic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mansouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Plevova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1007" to="1016" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26675346</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Rose-Zerilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Larrayoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Edelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blakemore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="2179" to="2186" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27282254</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jeromin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weissmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Haferlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dicker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Grossmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="108" to="117" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24113472</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Oscier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Rose-Zerilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Winkelmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gonzalez De Castro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Forster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="468" to="475" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23086750</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Stilgenbauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Schnaiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Paschka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dohner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="3247" to="3254" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24652989</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Recurrent mutations refine prognosis in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Baliakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hadzidimitriou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Minga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="329" to="336" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 24943832</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Spina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bruscaggin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ciardullo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="1403" to="1412" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23243274</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yasuda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sanjo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pages</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kawano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Karasuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pouyssegur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="499" to="508" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18356083</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The transcription factors Egr2 and Egr3 are essential for the control of inflammation and antigen-induced proliferation of B and T cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sebastian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bhullar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ghaffari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="685" to="696" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 23021953</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Essential control of early B-cell development by Mef2 transcription factors</title>
		<author>
			<persName><forename type="first">J</forename><surname>Herglotz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Unrau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hauschildt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kriebitzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alawi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="572" to="581" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26660426</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Acquired initiating mutations in early hematopoietic cells of CLL patients</title>
		<author>
			<persName><forename type="first">F</forename><surname>Damm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mylonas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cosson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Della</forename><surname>Valle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mouly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1088" to="1101" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24920063</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Oakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seifert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Assenov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Przekopowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Ruppert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="253" to="264" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26780610</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hallek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Cheson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Catovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Caligaris-Cappio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dighiero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="page" from="5446" to="5456" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>PubMed: 18216293</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial</title>
		<author>
			<persName><forename type="first">D</forename><surname>Catovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Matutes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Oscier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Bezares</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="page" from="230" to="239" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note>PubMed: 17658394</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">F</forename><surname>Damm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kosmider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Gelsi-Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Renneville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Carbuccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hidalgo-Curtis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="page" from="3211" to="3218" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22343920</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Fast and accurate long-read alignment with Burrows-Wheeler transform</title>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Durbin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="589" to="595" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note>PubMed: 20080505</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Koboldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Mclellan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="568" to="576" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22300766</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">ANNOVAR: functional annotation of genetic variants from highthroughput sequencing data</title>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hakonarson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page">e164</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">SF3B1 and other novel cancer genes in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stojanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sougnez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stevenson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">365</biblScope>
			<biblScope unit="page" from="2497" to="2506" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 22150006</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">V</forename><surname>Quesada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Conde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Ordonez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bassaganyas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="47" to="52" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 22158541</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation</title>
		<author>
			<persName><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Trifonov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Khiabanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">208</biblScope>
			<biblScope unit="page" from="1389" to="1401" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21670202</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness</title>
		<author>
			<persName><forename type="first">M</forename><surname>Messina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Giudice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Khiabanian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chiaretti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2378" to="2388" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24550227</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Evolution and impact of subclonal mutations in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Landau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Carter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stojanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="714" to="726" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23415222</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Puente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pinyol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Quesada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Conde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Ordonez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Villamor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">475</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>PubMed: 21642962</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schuh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Becq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Humphray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alexa</forename><forename type="middle">A</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Clifford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="4191" to="4196" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 22915640</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ojha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Secreto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Rabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ayres-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tschumper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Dyke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="2395" to="2398" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 25034147</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm</title>
		<author>
			<persName><forename type="first">P</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Henikoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Ng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Protoc</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1073" to="1081" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>PubMed: 19561590</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Gale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="5426" to="5434" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25605254</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped Bcell receptors</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baliakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hadzidimitriou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Moysiadis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Plevova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="959" to="967" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 27198719</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Strefford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Baliakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Agathangelidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malcikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Plevova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="2196" to="2199" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23558524</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The frequency of TP53 gene defects differs between chronic lymphocytic leukaemia subgroups harbouring distinct antigen receptors</title>
		<author>
			<persName><forename type="first">J</forename><surname>Malcikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stalika</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Plevova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trbusek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mansouri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="page" from="621" to="625" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>PubMed: 24725250</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Skowronska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Oldreive</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Richards</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="4524" to="4532" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>PubMed: 23091097</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Targeted nextgeneration sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ljungstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mansouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Young</forename><forename type="middle">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Cortese</forename><forename type="middle">D</forename><surname>Navrkalova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="370" to="376" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25480502</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin</title>
		<author>
			<persName><forename type="first">V</forename><surname>Navrkalova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sebejova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zemanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kminkova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kubesova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Malcikova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1124" to="1131" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 23585524</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">J</forename><surname>Malcikova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stano-Kozubik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tichy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kantorova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pavlova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Tom</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="877" to="885" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>PubMed: 25287991</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders</title>
		<author>
			<persName><forename type="first">F</forename><surname>Damm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Chesnais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nagata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Scourzic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Okuno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="3169" to="3177" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>PubMed: 24047651</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Nadeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Delgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Royo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Baumann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Stankovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pinyol</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="2122" to="2130" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>PubMed: 26837699</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
